Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cardiol Therapeutics
(NQ:
CRDL
)
1.620
+0.040 (+2.53%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cardiol Therapeutics
< Previous
1
2
Next >
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
November 21, 2024
Via
AB Newswire
Topics
Economy
Exposures
Supply Chain
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
November 21, 2024
Via
AB Newswire
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
November 18, 2024
Via
AB Newswire
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
November 18, 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially...
Via
Newsfile
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
November 13, 2024
Via
AB Newswire
Topics
Electric Vehicles
Exposures
Electric Vehicles
Product Safety
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
November 07, 2024
Via
AB Newswire
Exposures
Product Safety
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
November 05, 2024
Via
AB Newswire
Topics
Government
Exposures
Political
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
October 23, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
October 22, 2024
Via
AB Newswire
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
September 12, 2024
Via
AB Newswire
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II...
Via
TheNewswire.com
Exposures
Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
June 13, 2024
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce...
Via
Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via
AB Newswire
Topics
ETFs
Exposures
Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record...
Via
TheNewswire.com
Topics
ETFs
Exposures
Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
May 28, 2024
Via
AB Newswire
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Exposures
Product Safety
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Via
Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via
Get News
Topics
Death
Exposures
Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary...
Via
TheNewswire.com
Topics
Death
Exposures
Death
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac...
Via
Newsfile
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center,...
Via
Newsfile
Sidoti's Micro-Cap Virtual May Conference
May 09, 2023
Via
ACCESSWIRE
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Via
Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
July 13, 2022
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the...
Via
FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
June 21, 2022
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly...
Via
FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.